Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Retained Earnings (2017 - 2025)

Serina Therapeutics' Retained Earnings history spans 9 years, with the latest figure at -$60.2 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 44.7% year-over-year to -$60.2 million; the TTM value through Sep 2025 reached -$60.2 million, down 44.7%, while the annual FY2024 figure was -$44.3 million, 33.58% down from the prior year.
  • Retained Earnings for Q3 2025 was -$60.2 million at Serina Therapeutics, down from -$55.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$33.2 million in Q4 2023 and bottomed at -$127.6 million in Q3 2023.
  • The 5-year median for Retained Earnings is -$101.6 million (2021), against an average of -$84.4 million.
  • The largest annual shift saw Retained Earnings tumbled 125532.1% in 2021 before it soared 71.45% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$105.7 million in 2021, then decreased by 9.89% to -$116.2 million in 2022, then surged by 71.45% to -$33.2 million in 2023, then plummeted by 33.58% to -$44.3 million in 2024, then tumbled by 35.76% to -$60.2 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Retained Earnings are -$60.2 million (Q3 2025), -$55.6 million (Q2 2025), and -$49.1 million (Q1 2025).